Bicycle Therapeutics Ltd
$ 5.28
4.35%
15 Apr - close price
- Market Cap 368,053,000 USD
- Current Price $ 5.28
- High / Low $ 5.30 / 5.03
- Stock P/E N/A
- Book Value 8.79
- EPS -3.16
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.31 %
- 52 Week High 9.55
- 52 Week Low 4.24
About
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
Analyst Target Price
$12.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-10-29 | 2025-08-08 | 2025-04-30 | 2025-02-18 | 2024-10-31 | 2024-08-06 | 2024-05-02 | 2024-02-20 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.29 | -0.85 | -1.14 | -0.88 | -0.8144 | -0.74 | -0.77 | -0.62 | -1.16 | -1.26 | -1.41 | -1.3 |
| Estimated EPS | -0.9372 | -0.9708 | -0.94 | -0.8088 | -0.8536 | -0.78 | -1.1 | -1.24 | -1.23 | -1.17 | -1.29 | -1.07 |
| Surprise | 0.6472 | 0.1208 | -0.2 | -0.0712 | 0.0392 | 0.04 | 0.33 | 0.62 | 0.07 | -0.09 | -0.12 | -0.23 |
| Surprise Percentage | 69.0568% | 12.4433% | -21.2766% | -8.8032% | 4.5923% | 5.1282% | 30% | 50% | 5.6911% | -7.6923% | -9.3023% | -21.4953% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.52 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BCYC
2026-04-15 10:39:23
The article suggests Bicycle Therapeutics (BCYC) might see a trend reversal after a 20.2% price drop over four weeks. It aims to explain the factors that could lead to this change in the stock's performance.
2026-04-15 01:39:23
RBC Capital has downgraded Bicycle Therapeutics plc (BCYC) stock. The article headline indicates a negative reassessment of the company's prospects by the investment bank. Further details would be needed to understand the reasons behind the downgrade and the new rating and price target.
2026-04-08 14:40:40
Morgan Stanley has lowered its price target for Bicycle Therapeutics (BCYC) from $13.00 to $12.00, while maintaining an Equal-Weight rating. This adjustment follows similar price target reductions by other analysts in March 2026. Despite these reductions, the average one-year price target from 11 analysts suggests a significant upside of 153.01% from the current price, with an average brokerage recommendation of "Outperform."
2026-04-07 23:39:05
RBC Capital has adjusted its price target for Bicycle Therapeutics plc (BCYC) downward from $11 to $7. This revision indicates a more cautious outlook from the firm regarding the company's future stock performance.
2026-04-07 00:11:02
Bicycle Therapeutics CEO Kevin Lee sold 5,967 shares on April 2nd and an additional 1,716 shares on April 6th to cover tax withholding on vested equity, reducing his total holdings by 0.96%. The company's stock traded down 3.2% to $4.89 with below-average volume. Despite beating EPS and revenue estimates, Bicycle Therapeutics remains unprofitable, and analysts have a mixed "Hold" rating with an average target price of $14.50.
2026-04-06 22:11:02
Michael Charles Ferguson, an officer at Bicycle Therapeutics (BCYC), sold 1,772 Ordinary Shares in two transactions on April 2 and April 6, 2026. These sales, totaling approximately $8,736, were mandatory "sell to cover" arrangements to satisfy statutory tax withholding obligations arising from the vesting of his Restricted Stock Units (RSUs), and not discretionary market sales. Following these transactions, Ferguson directly holds 96,136 Ordinary Shares in the company.
